SG11202108552QA - Compounds, compositions and methods - Google Patents
Compounds, compositions and methodsInfo
- Publication number
- SG11202108552QA SG11202108552QA SG11202108552QA SG11202108552QA SG11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805263P | 2019-02-13 | 2019-02-13 | |
| US201962877232P | 2019-07-22 | 2019-07-22 | |
| PCT/US2020/018007 WO2020168011A1 (en) | 2019-02-13 | 2020-02-12 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108552QA true SG11202108552QA (en) | 2021-09-29 |
Family
ID=72043948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108552QA SG11202108552QA (en) | 2019-02-13 | 2020-02-12 | Compounds, compositions and methods |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11306077B2 (en) |
| EP (1) | EP3923935A4 (en) |
| JP (1) | JP2022520236A (en) |
| KR (1) | KR20210126036A (en) |
| CN (1) | CN113518618A (en) |
| AU (1) | AU2020223228A1 (en) |
| BR (1) | BR112021015639A2 (en) |
| CA (1) | CA3129609A1 (en) |
| CL (1) | CL2021002104A1 (en) |
| CO (1) | CO2021010490A2 (en) |
| CR (1) | CR20210426A (en) |
| IL (1) | IL285302A (en) |
| MA (1) | MA54953A (en) |
| MX (1) | MX2021009669A (en) |
| PE (1) | PE20212023A1 (en) |
| SA (1) | SA521430021B1 (en) |
| SG (1) | SG11202108552QA (en) |
| TW (1) | TW202045164A (en) |
| WO (1) | WO2020168011A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200037830A (en) | 2017-08-09 | 2020-04-09 | 데날리 테라퓨틱스 인크. | Compounds, compositions and methods |
| SG11202005561XA (en) | 2017-12-13 | 2020-07-29 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| CA3100715A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| MA54959A (en) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| JP2022536663A (en) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | Modulators of integrated stress response pathways |
| EP4117780A1 (en) | 2020-03-11 | 2023-01-18 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EP4232153A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| WO2022084448A1 (en) | 2020-10-22 | 2022-04-28 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| JP2023546226A (en) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Modulators of integrated stress response pathways |
| EP4263488A1 (en) * | 2020-12-18 | 2023-10-25 | Denali Therapeutics Inc. | Solid forms of a compound |
| WO2024032501A1 (en) * | 2022-08-08 | 2024-02-15 | 深圳众格生物科技有限公司 | Compound, pharmaceutical composition comprising same, and use thereof |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| WO2000023076A1 (en) | 1998-10-16 | 2000-04-27 | Suntory Limited | Aminophenoxyacetic acid derivatives as neuroprotectants |
| AR024077A1 (en) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | ANTIBACTERIAL COMPOUNDS |
| WO2001081317A1 (en) * | 2000-04-26 | 2001-11-01 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| AU2002338334B8 (en) * | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1 |
| MX2007002582A (en) | 2004-09-02 | 2008-01-14 | Vertex Pharma | Quinazolines useful as modulators of ion channels. |
| KR20080016577A (en) | 2005-05-24 | 2008-02-21 | 아스트라제네카 아베 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| NZ569293A (en) * | 2005-12-23 | 2011-10-28 | Zealand Pharma As | Modified lysine-mimetic compounds |
| US20080221100A1 (en) | 2006-10-20 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| WO2008152603A1 (en) | 2007-06-15 | 2008-12-18 | Actelion Pharmaceuticals Ltd | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives |
| MX2011005905A (en) | 2008-12-12 | 2011-06-20 | Actelion Pharmaceuticals Ltd | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives. |
| EP2435040A2 (en) | 2009-05-28 | 2012-04-04 | President and Fellows of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| AP3631A (en) | 2009-06-17 | 2016-03-08 | Vertex Pharma | Inhibitors of influenza viruses replication |
| TWI538905B (en) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | Bicyclo [3.2.1] octyl amide derivatives and uses of same |
| JP6013375B2 (en) | 2011-02-24 | 2016-10-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Thiazolylphenyl-benzenesulfonamide derivatives as kinase inhibitors |
| HUE038714T2 (en) | 2011-03-10 | 2018-11-28 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
| HRP20240097T1 (en) | 2011-04-22 | 2024-03-29 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| CN104114025B (en) * | 2012-02-14 | 2017-11-07 | 先正达参股股份有限公司 | Nematicide cis (miscellaneous) aryl cyclopropyl carboxamides derivatives |
| RU2015116816A (en) | 2012-10-02 | 2016-11-27 | Сумитомо Дайниппон Фарма Ко., Лтд. | IMIDAZOLE DERIVATIVE |
| US9447026B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014233520B2 (en) * | 2013-03-15 | 2019-02-21 | The Regents Of The University Of California | Modulators of the eIF2alpha pathway |
| US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| SG10201809260XA (en) | 2014-04-04 | 2018-11-29 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6833677B2 (en) | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Bicyclic compound |
| NZ730728A (en) | 2014-11-20 | 2022-04-29 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
| AU2016222575A1 (en) | 2015-02-25 | 2017-09-07 | William Marsh Rice University | Desacetoxytubulysin H and analogs thereof |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| MA42038A (en) | 2015-05-05 | 2018-03-14 | Bayer Pharma AG | AMIDO SUBSTITUTE CYCLOHEXANE DERIVATIVES |
| TW201718557A (en) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | Pyrazolyl substituted tetrahydropyranylsulfones |
| TW201808888A (en) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
| TW201808903A (en) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
| TW201808914A (en) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
| TWI844006B (en) * | 2016-05-05 | 2024-06-01 | 美商嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
| BR112018075598A2 (en) | 2016-06-08 | 2019-03-26 | Glaxosmithkline Intellectual Property Development Limited | chemical compounds |
| CA3026983A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| DK3481819T3 (en) | 2016-07-06 | 2022-07-25 | Acquist Llc | COMPOUNDS AND USE THEREOF FOR REDUCING URIC ACID LEVELS |
| JOP20190072A1 (en) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors |
| KR20190087622A (en) | 2016-12-08 | 2019-07-24 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | (DLK) kinase bicyclic [1.1.1] pentane inhibitor |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2018227067A1 (en) * | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| BR112020000122A2 (en) * | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivatives of n- (3- (2- (4-chlorophenoxy) acetamido) bicyclo [1.1.1] pentan-1-yl) -2-cyclobutane-1-carboxamide and related compounds as inhibitors of atf4 for treatment against cancer and other diseases |
| WO2019008507A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| KR20200037830A (en) * | 2017-08-09 | 2020-04-09 | 데날리 테라퓨틱스 인크. | Compounds, compositions and methods |
| HUE062446T2 (en) | 2017-09-01 | 2023-11-28 | Denali Therapeutics Inc | Compounds, compositions and methods |
| WO2019054430A1 (en) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | Amide compound having aromatic heterocycle |
| WO2019090078A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| UY37956A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
| UY37957A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
| JP7324196B2 (en) | 2017-11-02 | 2023-08-09 | カリコ ライフ サイエンシーズ エルエルシー | Modulators of integrated stress pathways |
| CN112218869A (en) | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | Modulators of integrated stress pathways |
| CA3080959A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| IL274367B2 (en) | 2017-11-02 | 2023-10-01 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37958A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
| SG11202005561XA (en) | 2017-12-13 | 2020-07-29 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| EP3768660A1 (en) | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| BR112021000332A2 (en) | 2018-07-09 | 2021-04-06 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI832295B (en) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | Prodrug modulators of the integrated stress pathway |
| MA54959A (en) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| BR112021020402A2 (en) * | 2019-04-23 | 2021-12-07 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| AU2020266592A1 (en) | 2019-04-30 | 2021-12-02 | Abbvie Inc. | Substituted cyclolakyls as modulators of the integrated stress pathway |
| CA3138182A1 (en) | 2019-04-30 | 2020-11-05 | Calico Life Sciences Llc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| MX2022009243A (en) * | 2020-01-28 | 2022-08-16 | Evotec Int Gmbh | Modulators of the integrated stress response pathway. |
| EP4263488A1 (en) | 2020-12-18 | 2023-10-25 | Denali Therapeutics Inc. | Solid forms of a compound |
-
2020
- 2020-02-12 SG SG11202108552QA patent/SG11202108552QA/en unknown
- 2020-02-12 WO PCT/US2020/018007 patent/WO2020168011A1/en active Application Filing
- 2020-02-12 MX MX2021009669A patent/MX2021009669A/en unknown
- 2020-02-12 CR CR20210426A patent/CR20210426A/en unknown
- 2020-02-12 EP EP20755645.7A patent/EP3923935A4/en active Pending
- 2020-02-12 JP JP2021547076A patent/JP2022520236A/en not_active Withdrawn
- 2020-02-12 AU AU2020223228A patent/AU2020223228A1/en active Pending
- 2020-02-12 BR BR112021015639-9A patent/BR112021015639A2/en unknown
- 2020-02-12 PE PE2021001317A patent/PE20212023A1/en unknown
- 2020-02-12 KR KR1020217027796A patent/KR20210126036A/en active Search and Examination
- 2020-02-12 TW TW109104414A patent/TW202045164A/en unknown
- 2020-02-12 CN CN202080017506.7A patent/CN113518618A/en active Pending
- 2020-02-12 CA CA3129609A patent/CA3129609A1/en active Pending
- 2020-02-12 MA MA054953A patent/MA54953A/en unknown
-
2021
- 2021-05-28 US US17/334,587 patent/US11306077B2/en active Active
- 2021-08-02 IL IL285302A patent/IL285302A/en unknown
- 2021-08-10 CO CONC2021/0010490A patent/CO2021010490A2/en unknown
- 2021-08-10 CL CL2021002104A patent/CL2021002104A1/en unknown
- 2021-08-10 SA SA521430021A patent/SA521430021B1/en unknown
-
2022
- 2022-03-23 US US17/702,718 patent/US11958840B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021009669A (en) | 2021-10-13 |
| IL285302A (en) | 2021-09-30 |
| EP3923935A4 (en) | 2022-10-26 |
| CO2021010490A2 (en) | 2021-08-30 |
| US11306077B2 (en) | 2022-04-19 |
| US20210292311A1 (en) | 2021-09-23 |
| CR20210426A (en) | 2021-09-30 |
| CA3129609A1 (en) | 2020-08-20 |
| CL2021002104A1 (en) | 2022-04-08 |
| PE20212023A1 (en) | 2021-10-18 |
| JP2022520236A (en) | 2022-03-29 |
| AU2020223228A1 (en) | 2021-08-26 |
| TW202045164A (en) | 2020-12-16 |
| KR20210126036A (en) | 2021-10-19 |
| MA54953A (en) | 2021-12-22 |
| EP3923935A1 (en) | 2021-12-22 |
| BR112021015639A2 (en) | 2021-10-05 |
| WO2020168011A1 (en) | 2020-08-20 |
| US20230114472A1 (en) | 2023-04-13 |
| CN113518618A (en) | 2021-10-19 |
| SA521430021B1 (en) | 2024-08-11 |
| US11958840B2 (en) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285215A (en) | Immunomodulators, compositions and methods thereof | |
| IL272089B1 (en) | Compounds, compositions and methods | |
| IL285302A (en) | Compounds, compositions and methods | |
| PL3676297T3 (en) | Compounds, compositions and methods | |
| EP3924341A4 (en) | Compounds, compositions and methods | |
| GB201903287D0 (en) | Composition | |
| SG11202006994XA (en) | Antibacterial compounds, compositions thereof, and methods using same | |
| GB201901099D0 (en) | Methods, uses and compositions | |
| GB202017595D0 (en) | Compositions, and methods and uses relating thereto | |
| GB2576614B (en) | Compositions, uses and methods | |
| EP4196125A4 (en) | Compounds, compositions and methods | |
| GB201804163D0 (en) | Uses, compositions and methods | |
| IL287120A (en) | Compounds, compositions and methods | |
| EP4175642A4 (en) | Compounds, compositions and methods | |
| IL270505B1 (en) | Compounds, compositions and methods | |
| GB202006716D0 (en) | Composition | |
| EP3807247A4 (en) | Photostabilizing compounds, compositions, and methods | |
| EP3806814A4 (en) | Photostabilizing compounds, compositions, and methods | |
| GB201911694D0 (en) | Composition | |
| GB201911454D0 (en) | Composition | |
| EP3741814C0 (en) | Composition | |
| GB201907225D0 (en) | Composition | |
| GB201903340D0 (en) | Composition | |
| GB201902054D0 (en) | Composition | |
| EP3807275A4 (en) | Photostabilizing compounds, compositions, and methods |